Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

TY - JOUR

T1 - Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

AU - Iversen, Kasper K

AU - Teisner, Børge

AU - Winkel, Per

AU - Gluud, Christian

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Hildebrandt, Per Rossen

AU - Hilden, Jørgen

AU - Kastrup, Jens

AU - The CLARICOR Trial Group

N1 - Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p

AB - OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p

U2 - 10.1016/j.atherosclerosis.2010.10.025

DO - 10.1016/j.atherosclerosis.2010.10.025

M3 - Journal article

C2 - 21093861

SN - 0021-9150

VL - 214

SP - 203

EP - 208

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -